News Agency
The Times

Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis

  • Written by PR Newswire

CHENGDU, China, Feb. 8, 2025 /PRNewswire/ -- KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (the "sNDA") of Stapokibart (anti-IL-4Rα monoclonal antibody, trade name: Kangyueda (康悦达), for the...

Read more: Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis

How Australian Businesses Can Prepare Their Websites for AI-Powered Search Results

Search is changing rapidly. While traditional search engines remain a major source of website traffic, customers are increasingly using AI-powered platforms to discover information, compare businesses and make purchasing decisions. For Australian businesses, this shift creates a new challenge: ensuring... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion